ArticleNature2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 142 papers.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed.
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Nature medicine · 2026Trial
- Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.Nature medicine · 2026Trial
- Glecirasib in KRASNature medicine · 2025Trial
- Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells.British journal of cancer · 2026Article
- Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.Experimental hematology & oncology · 2026Review
- Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.Research square · 2026Article
- KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.Science advances · 2026Article
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- Metabolic Response to an Individualized Multimodal Treatment Strategy in Advanced Pancreatic Adenocarcinoma: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Cancer research · 2026Article
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.Developmental cell · 2026Article
- Article
- Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies.Cancer science · 2026Review
- MYC in Oncogenesis and Therapeutic Implications.MedComm · 2026Review
- RAS Inhibitor RMC-7977 Blocks Vascular Overgrowth of NRASJournal of cellular and molecular medicine · 2026Article
- Pancreatic Cancer-Advances in the Last 50 Years.World journal of surgery · 2026Review
- From RAS inhibitor resistance to rational combination strategies.Nature medicine · 2026Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
66 authors.
Urszula N Wasko *Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Jingjing Jiang *Revolution Medicines, Redwood City, CA, USA.
Tanner C DaltonDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Alvaro Curiel-GarciaDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-6249-3267
A Cole EdwardsDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yingyun WangRevolution Medicines, Redwood City, CA, USA.
Bianca LeeRevolution Medicines, Redwood City, CA, USA.
Margo OrlenUniversity of Pennsylvania Perelman School of Medicine, Department of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-9834-6282
Sha TianCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Clint A StalneckerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-0570-4416
Kristina Drizyte-MillerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Marie MenardRevolution Medicines, Redwood City, CA, USA.
Julien DillyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4006-5285
Stephen A SastraDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Carmine F PalermoDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Marie C HasselluhnDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-9765-4075
Amanda R Decker-FarrellDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Stephanie ChangRevolution Medicines, Redwood City, CA, USA.ORCID 0009-0000-2026-5215
Lingyan JiangRevolution Medicines, Redwood City, CA, USA.
Xing WeiRevolution Medicines, Redwood City, CA, USA.
Yu C YangRevolution Medicines, Redwood City, CA, USA.
Ciara HellandRevolution Medicines, Redwood City, CA, USA.
Haley CourtneyRevolution Medicines, Redwood City, CA, USA.
Yevgeniy GindinRevolution Medicines, Redwood City, CA, USA.
Karl MuonioRevolution Medicines, Redwood City, CA, USA.
Ruiping ZhaoRevolution Medicines, Redwood City, CA, USA.
Samantha B KempUniversity of Pennsylvania Perelman School of Medicine, Department of Medicine, Philadelphia, PA, USA.
Cynthia ClendeninUniversity of Pennsylvania Perelman School of Medicine, Abramson Cancer Center, Philadelphia, PA, USA.ORCID 0000-0003-4535-2088
Rina SorUniversity of Pennsylvania Perelman School of Medicine, Abramson Cancer Center, Philadelphia, PA, USA.ORCID 0000-0003-2042-5746
William P VostrejsUniversity of Pennsylvania Perelman School of Medicine, Department of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-1659-0186
Priya S HibshmanDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Amber M AmparoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-3805-746X
Connor HennesseyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew G ReesThe Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-2987-7581
Melissa M RonanThe Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-4269-1404
Jennifer A RothThe Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-5117-5586
Jens BrodbeckRevolution Medicines, Redwood City, CA, USA.
Lorenzo TomassoniHerbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Basil BakirDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Nicholas D SocciBioinformatics Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Laura E HerringUNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-4496-7312
Natalie K BarkerUNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Junning WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
James M ClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brian M WolpinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0455-1032
John A ChabotDepartment of Surgery, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Michael D KlugerDepartment of Surgery, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Gulam A ManjiDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Kenneth Y TsaiDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0001-5325-212X
Miroslav SekulicDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Stephen M LaganaDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Andrea CalifanoDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Elsa QuintanaRevolution Medicines, Redwood City, CA, USA.
Zhengping WangRevolution Medicines, Redwood City, CA, USA.
Jacqueline A M SmithRevolution Medicines, Redwood City, CA, USA.ORCID 0000-0001-5028-8725
Matthew HolderfieldRevolution Medicines, Redwood City, CA, USA.
David WildesRevolution Medicines, Redwood City, CA, USA.ORCID 0009-0009-3855-7270
Scott W LoweCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5284-9650
Michael A BadgleyDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0701-6203
Robert H VonderheideUniversity of Pennsylvania Perelman School of Medicine, Department of Medicine, Philadelphia, PA, USA.ORCID 0000-0002-7252-954X
Ben Z StangerUniversity of Pennsylvania Perelman School of Medicine, Department of Medicine, Philadelphia, PA, USA.ORCID 0000-0003-0410-4037
Timour BaslanDepartment of Biomedical Sciences, School of Veterinary Medicine, The University of Pennsylvania, Philadelphia, PA, USA.
Channing J DerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-7751-2747
Mallika SinghRevolution Medicines, Redwood City, CA, USA. msingh@revmed.com.
Kenneth P OliveDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA. kenolive@columbia.edu.ORCID 0000-0002-3392-8994
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MVirology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Alexander Drilon, Piro Lito · 2007 to 2026
$31.2MIntegrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MSToP Cancer SPORE: Developmental Research ProgramP50CA257911 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jen Jen Yeh · 2022 to 2026
$12.9MStudying the evolution of drug resistance in prostate cancer at the single cell levelU54CA274506 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2023 to 2026
$9.1MThe Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2MTargeting undruggable RAS for cancer treatmentR35CA232113 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 2018 to 2024
$6.3MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MNCATS NIH HHS UL1 TR001873NCI NIH HHS F31 CA275260NCI NIH HHS F32 CA232529NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA257911NCI NIH HHS R01 CA215607NCI NIH HHS R01 CA229803NCI NIH HHS R01 CA266558NCI NIH HHS R01 CA276268NCI NIH HHS R35 CA232113NCI NIH HHS T32 CA009140NCI NIH HHS T32 CA009156NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA217858NCI NIH HHS U01 CA272610NCI NIH HHS U01 CA274312NCI NIH HHS U54 CA274506NIAID NIH HHS K08 AI106953NIDDK NIH HHS P30 DK132710NIGMS NIH HHS T32 GM119999NIH HHS S10 OD012351NIH HHS S10 OD021764NIH HHS S10 OD032433
Abstract
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations
Indexed as
Antineoplastic AgentsCarcinoma, Pancreatic DuctalGuanosine TriphosphatePancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsApoptosisCell Line, TumorCell ProliferationDisease Models, AnimalDNA Copy Number VariationsDrug Resistance, NeoplasmFemaleGenes, mycGTP PhosphohydrolasesHumansAntineoplastic AgentsGTP PhosphohydrolasesGuanosine TriphosphateHRAS protein, humanKRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.